Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    laq-ms-305
Show Display Options
Rank Status Study
1 Active, not recruiting The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg;   Drug: Matching Placebo;   Drug: Laquinimod 1.2 mg

Indicates status has not been verified in more than two years